Last updated: April 25, 2026
Who supplies tobramycin (active pharmaceutical ingredient) for combination products?
Commercial ophthalmic and otic products that combine tobramycin with dexamethasone typically source tobramycin through dedicated API manufacturers and scale-through suppliers that cover sterile ophthalmic/otic systems. The supplier set is product- and market-dependent, but the governing constraint is the API’s regulatory status in the target jurisdiction (US FDA, EU EMA, UK MHRA, and other local agencies).
Below are the supplier channels and the supplier types that actually matter for procurement and formulation programs.
Supplier types that deliver tobramycin + dexamethasone combinations
- API manufacturers of tobramycin sulfate (or tobramycin)
- Provide a compliant API for sterile ophthalmic/otic products.
- Sterile drug product manufacturers
- Build the final container-closure and sterile fill-finish for the combination.
- End-to-end contract manufacturing organizations (CMOs)
- Source API (including tobramycin), formulate, sterilize, fill, and package.
- Local distributors for market access
- Sell finished drug products or API under local compliance.
Who supplies dexamethasone (active pharmaceutical ingredient) in these combinations?
Dexamethasone for ophthalmic/otic products is commonly supplied as dexamethasone (base) or dexamethasone sodium phosphate depending on the formulation. For tobramycin-dexamethasone combinations, contract manufacturers typically select dexamethasone forms and specifications aligned to the product file and sterility process.
Typical supply chain pattern for dexamethasone
- API manufacturer supplies dexamethasone grade aligned to ophthalmic/otic impurity profile needs.
- CMO / sterile fill-finish site uses that API in the validated formulation and sterile processing.
Which firms show up as likely sources across commercial tobramycin + dexamethasone products?
A practical procurement list for investors and R&D teams focuses on: (1) API suppliers named in regulatory submissions, (2) sterile ophthalmic/otic fill-finish CMOs with track record, and (3) finished-dose holders distributing the combination in key markets.
Finished-dose holders and branded product suppliers (supply-side signal)
The presence and longevity of combination products is the most direct signal of an established supplier ecosystem, because these products require repeatable sterile manufacturing and validated API sourcing. Commonly marketed tobramycin + dexamethasone ophthalmic/otic products include the well-known brand-level combinations across multiple regions (e.g., Tobradex-style combinations). These brands typically use a mix of global API sourcing plus validated sterile manufacturing sites.
Regulatory data points that determine “supplier”
Procurement and licensing decisions in pharma treat the following as decisive:
- API manufacturer and grade referenced in the approved product dossier.
- Drug product manufacturer (sterile manufacturing site) on labels and approvals.
- DMF/CEP and application references used by the finished-dose manufacturer.
What supplier list is available from public regulatory sources?
Public sources that can be used to map suppliers include:
- FDA Orange Book for product-level references and applicant/manufacturer data.
- FDA Drug Master File (DMF) database for API manufacturer relationships (when referenced by approved applications).
- EMA EPAR assessments and national dossiers for EU.
- CEP/EDQM (for EU) filings that indicate API control and qualified manufacturers.
However, a complete and accurate “supplier list” for tobramycin and dexamethasone requires product-specific dossier mapping (labeler/applicant plus referenced DMFs or CEPs). Without tying to a specific finished drug product (strength, dosage form, market authorization), the supplier list becomes ambiguous and risks mixing incompatible API forms (tobramycin sulfate vs tobramycin; dexamethasone base vs dexamethasone sodium phosphate) and incompatible regulatory grades.
Actionable procurement approach (company-level)
To generate a supplier roster that can be used for sourcing, contracting, or diligence, teams generally do the following:
- Start from the approved finished-dose product label in the jurisdiction (US/EU/UK or target country).
- Extract applicant/holder and manufacturing sites from the approval record.
- Identify referenced API filings (DMF/CEP/Article references) tied to that product.
- Map DMF/CEP holder(s) back to API manufacturer(s).
- Confirm sterile fill-finish site and packaging lines via label and manufacturing record.
This yields a defensible list for procurement because it ties the supplier to a specific regulated product submission pathway.
Key Takeaways
- “Suppliers for tobramycin and dexamethasone” must be mapped to a specific approved finished-dose product because API form (salt), grade, and dossier references determine the real supplier list.
- Regulatory product records (Orange Book/EPAR/CEP/DMF references) drive the supplier truth for both APIs and sterile drug product manufacturing sites.
- A correct supplier roster for this combination is built by linking finished-dose applicants and manufacturing sites to the referenced API filings.
FAQs
1) Are tobramycin and dexamethasone the same supplier across all combination products?
No. Even when the API names match, filings often reference different API forms and grades, which changes the qualified suppliers tied to each dossier.
2) What is the most reliable way to identify the real API supplier?
Use the finished-dose approval record for the target market, then trace referenced API filings (DMF/CEP or equivalent dossier references).
3) Do sterile fill-finish manufacturers supply the APIs too?
Often they source API under approved supply agreements, but the API manufacturer is still determined by the regulatory references in the product dossier.
4) Does the strength or dosage form change supplier requirements?
Yes. Ophthalmic vs otic, preservative systems, and container-closure types affect validated formulation and sterile process constraints, which can change qualified suppliers.
5) Why can public brand-name suppliers differ from actual manufacturing suppliers?
Brand holders may contract manufacturing and API supply to third parties; the authoritative supplier is the manufacturing site and the referenced API filing in the approval record.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] U.S. Food and Drug Administration. Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-master-files-dmfs
[3] European Medicines Agency. EPAR (European public assessment report) for authorized medicines. https://www.ema.europa.eu/en/medicines
[4] European Directorate for the Quality of Medicines (EDQM). Certificates of Suitability (CEPs) database. https://www.edqm.eu/en/cep_search.php
